Phase I/II Trial of AGS-003
Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.
DURHAM, North CarolinaArgos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.
Articles in this issue
Exjade Gains Approval in EU
Study Questions the Need for Maintenance Therapy in Metastatic Colorectal Cancer
President's Cancer Panel Assesses Progress in Two Areas
Proposed Medicare OPPS Rule Draws Fire for Its 'Inadequate Reimbursement'
Cognitive Rx Reduces Depression in Breast Ca Pts
Nurses Develop Evidence-Based Guidelines for Mucositis
Anastrozole Therapy for Breast Cancer Affects Bone Health
Is Demand for Trial Subjects Outpacing Supply?
Postchemo Disappearance of Liver Mets Doesn't Mean Cure
Aromasin-Related Bone Loss Affected by Vitamin D Levels
Melanoma Mets Regress After Gene Therapy
Phase I/II Trial of AGS-003
Short Course of Preoperative Radiotherapy Improves Outcomes in Patients With Resectable Rectal Cancer
President Bush Names Niederhuber NCI Director
Lack of EGFR Expression in Colon Ca Can Be Misleading
Recent Videos
